Yes, against current strain. When flu mutates, the shot changes too.
The shot you got few years back still works against that particular strain, but not against new ones. You don't get booster of the same vaccine, you get new shot for new strain.
The current shot for covid may have been effective (despite side effects) against original Wuhan strain, but not against delta strain.
Just as delta, this new "omicron" variant got mutated spike proteins that mRNA suppose to tech your body to identify and fight against. Thus, the current so called "vaccine" is useless.
Tell me what is the difference between injecting a set of proteins isolated from a live virus and the injection of a synthesized piece of the genetic code of those proteins.
That is what an mRNA vaccine is. It's just a modern version of the old live or denatured virus vaccines.
Yes, against current strain. When flu mutates, the shot changes too.
The shot you got few years back still works against that particular strain, but not against new ones. You don't get booster of the same vaccine, you get new shot for new strain.
The current shot for covid may have been effective (despite side effects) against original Wuhan strain, but not against delta strain.
Just as delta, this new "omicron" variant got mutated spike proteins that mRNA suppose to tech your body to identify and fight against. Thus, the current so called "vaccine" is useless.
A look at how this vaccine technology has been in the works for decades.
publichealth.jhu.edu
Tell me what is the difference between injecting a set of proteins isolated from a live virus and the injection of a synthesized piece of the genetic code of those proteins.
That is what an mRNA vaccine is. It's just a modern version of the old live or denatured virus vaccines.
One is fake and the other is not. One gives very limited memory the other gives longer memory. T Cell memory. One is TRADITIONAl and one is EXPERIMENTAL.
Covaxin from India is the ONLY TRADITIONAL VACCINE OUT THERE. It is a vector based vaccine.
So. tell me about how the mRNA vaccine is supposed to stay in the injection site. And is it good if it travels through the body????????????????
One is fake and the other is not. One gives very limited memory the other gives longer memory. T Cell memory. One is TRADITIONAl and one is EXPERIMENTAL.
Covaxin from India is the ONLY TRADITIONAL VACCINE OUT THERE. It is a vector based vaccine.
So. tell me about how the mRNA vaccine is supposed to stay in the injection site. And is it good if it travels through the body????????????????
mRNA vaccines represent a promising alternative to conventional vaccine approaches, but their application has been hampered by instability and delivery issues. Here, Pardi and colleagues discuss recent advances in mRNA vaccine technology, assess mRNA vaccines currently in development for cancer...
mRNA vaccines represent a promising alternative to conventional vaccine approaches, but their application has been hampered by instability and delivery issues. Here, Pardi and colleagues discuss recent advances in mRNA vaccine technology, assess mRNA vaccines currently in development for cancer...
mRNA vaccines represent a promising alternative to conventional vaccine approaches because of their high potency, capacity for rapid development and potential for low-cost manufacture and safe administration. However, their application has until ...
www.ncbi.nlm.nih.gov
Over the past decade, major technological innovation and research investment have enabled mRNA to become a promising therapeutic tool in the fields of vaccine development and protein replacement therapy. The use of mRNA has several beneficial features over subunit, killed and live attenuated virus, as well as DNA-based vaccines. First, safety: as mRNA is a non-infectious, non-integrating platform, there is no potential risk of infection or insertional mutagenesis. Additionally, mRNA is degraded by normal cellular processes, and its in vivo half-life can be regulated through the use of various modifications and delivery methods9–12. The inherent immunogenicity of the mRNA can be down-modulated to further increase the safety profile9,12,13. Second, efficacy: various modifications make mRNA more stable and highly translatable9,12,13. Efficient in vivo delivery can be achieved by formulating mRNA into carrier molecules, allowing rapid uptake and expression in the cytoplasm (reviewed in REFS 10,11). mRNA is the minimal genetic vector; therefore, anti-vector immunity is avoided, and mRNA vaccines can be administered repeatedly. Third, production: mRNA vaccines have the potential for rapid, inexpensive and scalable manufacturing, mainly owing to the high yields of in vitro transcription reactions.
The mRNA vaccine field is developing extremely rapidly; a large body of preclinical data has accumulated over the past several years, and multiple human clinical trials have been initiated. In this Review, we discuss current mRNA vaccine approaches, summarize the latest findings, highlight challenges and recent successes, and offer perspectives on the future of mRNA vaccines. The data suggest that mRNA vaccines have the potential to solve many of the challenges in vaccine development for both infectious diseases and cancer.
A look at how this vaccine technology has been in the works for decades.
publichealth.jhu.edu
THERE’S A BIG GAP BETWEEN WHEN THE FIRST MRNA FLU VACCINE WAS TESTED IN MICE IN THE 1990S AND WHEN THE FIRST MRNA VACCINES FOR RABIES WERE TESTED IN HUMANS IN 2013. WHAT WAS HAPPENING IN THE INTERIM?
SO, WHAT HAPPENED ONCE THEY FIGURED OUT THIS TECHNOLOGY?
The first mRNA vaccines using these fatty envelopes were developed against the deadly Ebola virus, but since that virus is only found in a limited number of African countries, it had no commercial development in the U.S.
mRNA vaccines represent a promising alternative to conventional vaccine approaches because of their high potency, capacity for rapid development and potential for low-cost manufacture and safe administration. However, their application has until ...
www.ncbi.nlm.nih.gov
Over the past decade, major technological innovation and research investment have enabled mRNA to become a promising therapeutic tool in the fields of vaccine development and protein replacement therapy. The use of mRNA has several beneficial features over subunit, killed and live attenuated virus, as well as DNA-based vaccines. First, safety: as mRNA is a non-infectious, non-integrating platform, there is no potential risk of infection or insertional mutagenesis. Additionally, mRNA is degraded by normal cellular processes, and its in vivo half-life can be regulated through the use of various modifications and delivery methods9–12. The inherent immunogenicity of the mRNA can be down-modulated to further increase the safety profile9,12,13. Second, efficacy: various modifications make mRNA more stable and highly translatable9,12,13. Efficient in vivo delivery can be achieved by formulating mRNA into carrier molecules, allowing rapid uptake and expression in the cytoplasm (reviewed in REFS 10,11). mRNA is the minimal genetic vector; therefore, anti-vector immunity is avoided, and mRNA vaccines can be administered repeatedly. Third, production: mRNA vaccines have the potential for rapid, inexpensive and scalable manufacturing, mainly owing to the high yields of in vitro transcription reactions.
The mRNA vaccine field is developing extremely rapidly; a large body of preclinical data has accumulated over the past several years, and multiple human clinical trials have been initiated. In this Review, we discuss current mRNA vaccine approaches, summarize the latest findings, highlight challenges and recent successes, and offer perspectives on the future of mRNA vaccines. The data suggest that mRNA vaccines have the potential to solve many of the challenges in vaccine development for both infectious diseases and cancer.
The use of mRNA has several beneficial features over subunit, killed and live attenuated virus, as well as DNA-based vaccines. First, safety: as mRNA is a non-infectious, non-integrating platform, there is no potential risk of infection or insertional mutagenesis. Additionally, mRNA is degraded by normal cellular processes, and its in vivo half-life can be regulated through the use of various modifications and delivery methods9–12
